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Mapping eQTLs in the Norfolk Island Genetic Isolate
Identifies Candidate Genes for CVD Risk Traits
Miles C. Benton,1 Rod A. Lea,1 Donia Macartney-Coxson,2 Melanie A. Carless,3 Harald H. Go¨ring,3
Claire Bellis,3 Michelle Hanna,1,4 David Eccles,1 Geoffrey K. Chambers,5 Joanne E. Curran,3
Jacquie L. Harper,6 John Blangero,3 and Lyn R. Griffiths1,4,*
Cardiovascular disease (CVD) affects millions of people worldwide and is influenced by numerous factors, including lifestyle and
genetics. Expression quantitative trait loci (eQTLs) influence gene expression and are good candidates for CVD risk. Founder-effect ped-
igrees can provide additional power to map genes associated with disease risk. Therefore, we identified eQTLs in the genetic isolate of
Norfolk Island (NI) and tested for associations between these and CVD risk factors. We measured genome-wide transcript levels of blood
lymphocytes in 330 individuals and used pedigree-based heritability analysis to identify heritable transcripts. eQTLs were identified by
genome-wide association testing of these transcripts. Testing for association between CVD risk factors (i.e., blood lipids, blood pressure,
and body fat indices) and eQTLs revealed 1,712 heritable transcripts (p < 0.05) with heritability values ranging from 0.18 to 0.84. From
these, we identified 200 cis-acting and 70 trans-acting eQTLs (p < 1.843 107) An eQTL-centric analysis of CVD risk traits revealed mul-
tiple associations, including 12 previously associated with CVD-related traits. Trait versus eQTL regressionmodeling identified four CVD
risk candidates (NAAA, PAPSS1, NME1, and PRDX1), all of which have known biological roles in disease. In addition, we implicated
several genes previously associated with CVD risk traits, includingMTHFR and FN3KRP. We have successfully identified a panel of eQTLs
in the NI pedigree and used this to implicate several genes in CVD risk. Future studies are required for further assessing the functional
importance of these eQTLs and whether the findings here also relate to outbred populations.Introduction
Cardiovascular disease (CVD) is an abnormal function of
the heart or blood vessels. This can lead to an increase in
risk of heart attack, heart failure, and stroke, which are
the leading causes of death world-wide.1 It is well estab-
lished that genetic variants influence CVD risk, and
many genetic loci have been implicated in CVD risk traits,
such as hypertension, hyperlipidemia, hyperglycemia, and
obesity.2–4 Expression quantitative trait loci (eQTLs) repre-
sent human genomic regions harboring genetic variants
that confer a marked effect on transcript expression level
and are either proximal (cis-acting) or distal (trans-acting)
to the gene. It is well established that gene expression
levels exhibit genetic heritability.5,6 Many eQTLs have
been mapped with markers such as short tandem re-
peats7–9 and, more recently, SNPs via dense genome-wide
arrays.10–13 Genome-wide association studies (GWASs)
have identified multiple SNPs associated with risk of com-
mon diseases, and attention has now turned to explaining
the underlying molecular mechanisms. The aim of the ge-
netics of gene expression is to identify loci associated with
disease and specific gene expression.
Population- and pedigree-based studies have successfully
mapped numerous eQTLs.7,11,14 Isolated founder popula-
tions potentially provide increased power to detect the
underlying genetic architecture of certain complex dis-
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complexity, extended linkage disequilibrium (LD), and
the existence of large pedigrees compared to unrelated
outbred populations.4,17 A recent pedigree-based study
used genome-wide transcriptional profile data from
peripheral-blood mononuclear cells (PBMCs) obtained
from participants in the San Antonio Family Heart
Study7 to perform heritability and linkage analysis of the
pedigrees, which led to a detailed eQTL map and the
discovery of several functional variants associated with
CVD and metabolic disorders; the most significant finding
was 67 cis-regulated transcripts associated with high-den-
sity-lipoprotein (HDL) cholesterol levels.
This study examined a very large pedigree from the iso-
lated population of Norfolk Island (NI) to identify eQTLs
associated with CVD risk traits. The NI population is a
genetic isolate with strong family groups and a well-docu-
mented family genealogy.18,19 To date, the Norfolk Island
Health Study (NIHS) has collected data and samples for
1,199 Norfolk Islanders, 52% (n ¼ 624) of whom were
found to have direct links to the original founders. A large
multigenerational NI pedigree has been reconstructed with
this in-depth genealogical information.20 Several studies
have established admixture scores and the presence of
founder effects within the NI pedigree.20,21 This pedigree
has been shown to provide the statistical power to detect
genetic loci influencing complex traits via linkage and
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Compared to mainland Australia, NI has high rates of
CVD-related risk-factor traits, especially obesity. Reported
rates of type 2 diabetes (T2D [MIM 125853]) in the NI
population are similar to those in mainland Australia
(4%–8%), although the fact that a significantly higher pro-
portion of individuals have fasting blood glucose in excess
of these normal ranges suggests that T2D is underdiag-
nosed in the NI population.26 Research on the NI pedigree
has shown that traits for obesity, dyslipidaemia, blood
glucose, and hypertension exhibit a substantial genetic
component; heritability estimates range from 30% for
systolic blood pressure (SBP) to 63% for low-density-lipo-
protein (LDL) cholesterol.26 In addition, factor analysis
has identified ‘‘composite’’ phenotypes with high herita-
bility,22 suggesting that common gene(s) underlie CVD-
related phenotypes. Genetic linkage analysis in the NI
pedigree has successfully identified previously docu-
mented regions associated with CVD risk traits; the most
significant of these regions is on chromosome 1 (1p36)
and is associated with SBP.24
This study is based on the hypothesis that variation in
heritable gene expression in PBMCs contributes to CVD
risk-factor traits and, therefore, that mapped eQTLs also
correlate with these traits. Using genome-wide SNP and
gene expression data, we mapped eQTLs and interrogated
them for correlations with CVD risk traits. Using a
pedigree-based association approach, we have shown
that variation in CVD risk-factor traits can be partly ex-
plained by heritable variation in gene expression (a quan-
titative endophenotype) and have identified several genes
implicated in CVD risk.Material and Methods
Cohort Collection and Ethics
The NIHS has already been well established in previous
research.22,23,26 In this study, we used a group of individuals
selected from the ‘‘core’’ pedigree, meaning that they relate back
to the original founders, and we have phenotype and genotype in-
formation for them. The total number of core pedigree members
selected was 330 (this was adjusted to exclude individuals under
the age of 18 years). Baseline statistics were previously calculated
for all CVD-related traits—these include all the biochemical mea-
sures, as well as body-size and composition traits.26 Phenotypic
baseline statistics were calculated in R 2.15.2 (Table S1, available
online).27 The ‘‘complete’’ NI pedigree structure includes ~5,700
NI individuals spanning 11 generations and ~200 years.20 We
used SOLAR to estimate h2 (heritability) and power for this
extended pedigree (Figure S1). All individuals gave written
informed consent, and ethical approval was granted prior to the
commencement of the study by the Griffith University Human
Research Ethics Committee.
Metabolic Assessment of Disease Risk
A series of metabolic predictions of disease risk for metabolic syn-
drome (MetS [MIM 605552]), T2D, and CVD were calculated with
the available clinical data. All risk-assessment tools were converted
into custom R scripts. For MetS, the risk equation used was based1088 The American Journal of Human Genetics 93, 1087–1099, Deceon an established clinical MetS diagnosis according to the joint
recommendations of the International Diabetes Federation, Amer-
ican Heart Association, and National Heart, Lung, and Blood
Institute (NHLBI).28 The risk of developing T2D was estimated
with the Australian Diabetes Risk Assessment Tool (AUS-
DRISK),29 available as a self-completion form online. T2D risk in
the NI population was compared with that in mainland Australia
(data obtained from the Australian Diabetes, Obesity, and Lifestyle
Study [AusDiab] Report 2012; see Web Resources). The risk of
developing CVD in the next 5 years was estimated for each indi-
vidual with the PREDICT-CVD equation.30Genome-wide Expression
For gene expression analysis, blood was collected and stored
at 20C in PAXgene tubes (QIAGEN). PAXgene Blood miRNA
Kits (QIAGEN) were used for extracting total RNA according to
the manufacturer’s instructions, and RNA was assessed for quality
with the Bioanalyzer 2100 (Agilent Technologies). A total of
250 ng of RNA was amplified and labeled with the Illumina
TotalPrep-96 RNA Amplification Kit (Life Technologies) according
to the manufacturer’s instructions. Expression profiling was per-
formed with the HumanHT-12 v.4 Expression BeadChip Kit
(Illumina) with 750 ng of amplified RNA according to the
Whole-Genome Gene Expression Direct Hybridization Assay
Guide. Array images were scanned on the Illumina iScan and
analyzed initially with the Gene Expression Module from
GenomeStudio (v.2011.1). Background subtraction was applied,
and missing bead types were imputed with GenomeStudio. On
the basis of the number of expressed probes (at ‘‘detection
p values’’ % 0.05), mean raw expression values across probes,
and correlations (across probes) between samples, all samples
provided high-quality data, except for one sample that was of
questionable quality (this was removed). Significantly expressed
probes were then determined at a false-discovery rate of 5%
on the basis of p values generated in a binomial test on the counts
of samples in which a probe generated ‘‘detection p values’’% 0.05
(success) and > 0.05 (failure). Subsequently, the raw expression
levels of probes detecting significant expression were shifted by
a constant amount so that the minimum observed value of any
probe in any sample was 1.0; this was followed by log2 transforma-
tion and quantile normalization.Genome-wide SNP Genotyping
EDTA anticoagulated venous blood samples were collected from
all participants. Genomic DNA was extracted from blood buffy
coats via standard phenol-chloroform procedures. Genome-wide
genotyping was carried out with the Illumina Human610-Quad
v.1.0 BeadChip. Raw data from Illumina idat files was SNP geno-
typed in R with the CRLMM package.31 Genotype data then
underwent quality-control routines with PLINK.32 In brief, SNP
analysis was restricted to autosomal SNPs with a minor allele fre-
quency > 0.01, call rate > 0.95, and Hardy-Weinberg equilibrium
testing p value > 105. After quality control, 590,603 SNPs were
used for association analyses with expression. Genotype data
were then exported from PLINK and imported into the CRAN
package GenABEL33 for analysis.Statistical Analysis
Identification of eQTLs
We used SOLAR34 to estimate the power to detect heritability in
the NI population. We split normalized gene expression datamber 5, 2013
(23,323 transcripts) into smaller ‘‘packets’’ of 1,000 to facilitate
high-throughput batching by parallel processing via the SNOW
package in R. Analysis of transcript heritability was batched with
custom R scripts and the package GenABEL33 with the polygenic
model. The polygenic-model function implemented in GenABEL
is capable of estimating the narrow-sense heritability (h2) of a trait.
The polygenic model takes into account the fact that potentially
thousands of genetic variants contribute to a trait’s phenotype.
The function implemented in GenABEL maximizes the likelihood
of the data under a polygenic model with covariates and reports
twice negative maximum likelihood estimates and the inverse of
the variance-covariance matrix at the point of maximum likeli-
hood.33 GenABEL also estimates residuals of the trait and the
inverse of the variance-covariance matrix for further use in associ-
ation analysis with the mmscore function.33 The polygenic model
within GenABEL implements variance components defined to
account for linked major gene effects, background polygenic
effects, and environmental effects. Age and sex, as well as genetic
structure, which was assessed by principal-component analysis
with the KING35 program, were included as covariates. The top
two components (Table S3) were chosen as covariates because
we found that these explained the majority of the variance in
the outcomes being tested and because inclusion of additional,
less informative components only served to reduce the parsimony
of themodels. All heritable transcripts were then treated as pheno-
types, and batched GWASs were run. Themmscore function as im-
plemented in GenABEL was used. This function represents a
mixed-model approximation analysis for association between a
trait and genetic polymorphism and is specifically designed for as-
sociation testing in samples of related individuals. This allows for
per-SNP association testing using a polygenic (mixed)-model
approach.33 The study-wide significance was set on the basis of
the Meff (minimum effective number of tests) adjustment (p ¼
1.84 3 107). A series of custom filters were designed to identify
cis and trans eQTLs: the presence of multiple adjacent SNPs in a
peak (within 5 20 kb), a SNP- and chromosome-location filter, a
chromosome-quadrant filter, and a graphical filter (modifiedMan-
hattan plots with kern smoothing to facilitate peak identification).
All eQTLs were defined by the ‘‘tagging’’ SNP, the SNP that showed
the most significant association with the given transcript. A
custom R script was used for identifying the eQTLs that mapped
to genes previously associated with disease in the GWAS data-
base.36 The GWAS database was downloaded as a plain-text file
on February 10, 2013, so analysis was conducted on reported asso-
ciations up to that date.
eQTL-Centric Association Analysis
A set of 2,200 SNPs representing all of those surpassing the Meff-
adjusted threshold (1.84 3 107) within eQTL peaks were ex-
tracted and used as a basis for an eQTL-centric association analysis.
For this analysis, all CVD- and obesity-related phenotypes were
run in a GWAS-based approach in GenABEL33 with the use of
the extracted SNP set. A short list of traits was obtained with a
relaxed significance threshold of 1.0 3 102.
Correlation of Key Transcript(s) with Phenotype
To investigate the effects of expression on CVD phenotypes, we
performed stepwise regression modeling in R 2.15.227 by using a
forward-selection algorithm with the CVD phenotype as the
response variable. The forward-selection algorithm starts with no
variables in themodel and adds variables one by one to themodel.
At each step, the variable added is the one that most improves the
fit of the model as measured by the Akaike information criterion.
The regression model included the following set of covariates,The American Jouwhich were tested in a stepwise fashion: expression transcript
(one at a time), age, sex, kinship, and genetic structure (the top
two principal components of the complete SNP set were calculated
by KING35). Based on the identity-by-descent probability matrix,
kinship is an index of relatedness among individuals and is used
as a control for the effect of nonindependence among individuals
in the sample. It is generally used as a pairwise measure, but in this
instance, we generated an average kinship for each pedigree mem-
ber (calculated inGenABELwith the SNP data). Genetic structure is
assessed via principal-component analysis for characterizing pop-
ulation stratification (e.g., admixture), whereby the component
membership coefficient can be used in the adjustment for struc-
ture effects. Only themodels with the transcript as a significant co-
variate and an overall model p value of 0.05 were included. Model
p values were generated from an ANOVA using the F distribution,
which tests the null hypothesis that the coefficients represented in
the overall regression model (represented by R2) are equal to 0.
Protein-Protein Interaction Prediction
We used STRING v.9.148 to generate a schematic overview of pre-
dicted protein-protein interactions of the proteins encoded by
NME1 (MIM 156490), PRDX1 (MIM 176763), and PAPSS1 (MIM
603262). We used the default active prediction methods, which
include neighborhood, gene fusion, co-occurrence, coexpression,
experiments, databases, and text mining. The medium required
cutoff confidence score was set to 0.4; the minimum observed
was 0.410, and the maximum was 0.986.Results
Prevalence of CVD Risk Traits in the NI Population
It is well documented that the NI cohort shows an
increased prevalence of CVD-related risk traits.22,26 To
further confirm these and provide a proof-of-principle
baseline risk for our heritability and eQTL analyses, we
conducted risk assessment by using a range of established
tools that allowed us to report NI’s predicted risk in relation
to that of mainland Australia. MetS diagnosis is a well-
established predictor for risk of developing further dis-
eases, namely T2D and CVD. Clinical diagnosis of MetS
in the NI cohort was conducted according to the joint rec-
ommendations of the International Diabetes Federation,
American Heart Association, and NHLBI.37 MetS preva-
lence was 26.4% in the NI cohort participants for whom
appropriate phenotype data were available (Table S2). A
noticeable difference in prevalence between males (31%)
and females (23%) was observed. A recent estimate for
MetS prevalence in mainland Australia was approximately
22%.38 Risk of developing T2D was assessed with the AUS-
DRISK;29 43% of the NI cohort was classed as high risk, and
another 42% was identified as intermediate risk. Mainland
Australian data were generated with the AUSDRISK and
are documented within the AusDiab Report 2012. Thirty-
one percent of the mainland Australian cohort was
predicted to be at a high risk of developing T2D.
According to the PREDICT-CVD tool,30 7% of the NI
cohort was estimated to be at a high risk of developing
CVD over the next 5 years. This increased to 12% when
adjustments were made for MetS (as per the model below).rnal of Human Genetics 93, 1087–1099, December 5, 2013 1089
Figure 1. Density Histogram Displaying Significantly Heritable
Expression Transcripts in the NI PopulationPREDICT-CVD suggests that individuals with a moderate
risk or higher report to a clinician for further assessment
and analysis; according to these criteria, approximately
31% of the NI cohort would be in this bracket. All three
risk-assessment scores further highlight the increased risk
of developing CVD, MetS, and T2D in this population
and suggest the presence of underlying genetic risk factors.
Heritable Gene Expression Transcripts and Clinical
Associations
Prior to eQTL analyses, we filtered gene transcripts (probes)
to exclude those with undetectable expression and poor-
mapping, hybridization, and/or annotation issues. After
filtering, 23,323 transcripts remained for analysis, and
normalized expression values were submitted to heritabil-
ity analysis. SOLAR34 power calculations revealed 80%
power to detect transcripts at a heritability R 0.31
(Figure S1). We observed 1,712 significantly heritable tran-
scripts (p < 0.05) with a range of h2 from 0.15 to 0.84
(Figure 1, Table S4). Several of themost significantly herita-
ble transcripts are of potential biological relevance in the
context of CVD risk factors. The transcript for GM2A
(MIM 613109), a gene evolved in lipid metabolism, ex-
hibited h2 ¼ 0.79 in the NI cohort. In addition, PSAT1
(MIM 610936; transcript h2 ¼ 0.70), has been shown to
contain variants associated with visceral fat levels,39 and
the UTS2 (urotensin-2 [MIM 604097]) transcript showed
high h2 at 0.69 (UTS2 is an active vasoconstrictor in the
brain). Interestingly, the NI pedigree exhibits a higher inci-
dence of migraine than do other populations,25,40 which
makes further investigation of UTS2 particularly pertinent.
To interrogate potential biologically significant relation-
ships, we performed correlation analyses between all 1,712
heritable transcripts and 14 well-established CVD-related
clinical traits: SBP, diastolic blood pressure, pulse pressure
(PP), blood lipids (HDL, LDL, total cholesterol, and triglyc-
erides), plasma glucose, waist circumference (WC), hip
circumference, body mass index (BMI), waist-to-hip ratio
(WHR), weight, and body fat (BF). Using a stepwise regres-1090 The American Journal of Human Genetics 93, 1087–1099, Decesion model including age, sex, kinship, and genetic struc-
ture as covariates, we observed that, of these 14 clinical
traits, 7 (WHR, BF, weight, WC, SBP, PP, and HDL) showed
significant association with a range of expression tran-
scripts (transcript p% 0.05). Table 1 shows the most signif-
icant associations with an R2 value > 0.2. The strongest
correlation was seen between WHR and two separate tran-
scripts: ILMN_1683093 (R2 ¼ 0.46, transcript p ¼ 1.73 3
106, R2 p % 1 3 106), a probe within glycophorin B
(GYPB [MIM 111740]), and ILMN_2352921 (R2 ¼ 0.46,
transcript p ¼ 3.47 3 106, R2 p % 1 3 106), a
probe within bisphosphoglycerate mutase (BPGM [MIM
613896]). Interestingly, both of these genes play a func-
tional role in blood.41,42 BPGM is involved in glycolysis
and oxygen transport. ILMN_2352921 (tagging BPGM)
was also significantly associated with SBP (R2 ¼ 0.25, p %
2.01 3 105). These results strongly suggest that there is
a potentially biologically significant correlation between
heritable gene expression levels and CVD-related traits in
the NI population.
eQTL Mapping in the NI Population
Next, we mapped all heritable transcripts to specific
genomic loci (eQTLs). We conducted pedigree-based asso-
ciation analysis of approximately 590,000 SNPs with the
1,712 heritable transcripts. Because of the unique popula-
tion of NI, we needed to control for population genetic
structure and did so by factoring the top two genetic prin-
cipal components into the modeling process (see Material
and Methods for more details). To identify potential eQTL
peaks, we used a series of custom filters to interrogate chro-
mosome and physical position, as well as SNP proximity.
Peaks were deemed to be robust if two or more SNPs
(520 kb) passed a Meff-adjusted threshold (1.84 3 107).
We identified 270 robust eQTLs, of which 200 were cis-
acting and 70 were trans-acting (Table S5). Figure 2 shows
Manhattan plots for the three most significant cis-acting
eQTLs. Price et al. and others have also observed more
cis- than trans-acting eQTLs in similarly designed
studies.11,43 We generated a genome-wide eQTL map
(Figure 3) by plotting each eQTL as represented by its
most significantly associated SNP. This allowed easy visual-
ization of eQTL-rich regions, such as 6p21 and 12q13,
which are both significantly enriched with cis-eQTLs.
eQTL-Centric SNP Association with CVD Risk Factors
Recent work has suggested that trait-associated SNPs in
GWASs are more likely to be associated with eQTLs and,
as such, suggests that increased discovery of biologically
relevant loci should be facilitated if applied to past and
present GWASs.44,45 Therefore, we investigated potential
associations between robustly identified eQTLs and all
CVD-related risk factors (an eQTL-centric analysis). All
significant eQTL-associated SNPs (n ¼ 2,200) were interro-
gated for association with a given trait (via the above-
mentioned pedigree-based association approach). We reset
our significance threshold for this part of the study tomber 5, 2013
Table 1. Summary of Heritable Transcript versus Trait Associations
Trait No. of transcripts h2_trans_min h2_trans_max R2_model_min R2_model_max Genes
WHR 174 0.19 0.64 0.42 0.46 166
BF 407 0.16 0.74 0.36 0.42 387
Weight 249 0.16 0.78 0.35 0.40 240
WC 222 0.15 0.74 0.30 0.37 209
SBP 124 0.22 0.74 0.24 0.28 122
PP 101 0.23 0.60 0.23 0.27 100
HDL 3 0.27 0.36 0.20 0.20 3
Abbreviations are as follows: BF, body fat; HDL, high-density lipoprotein; PP, pulse pressure; SBP, systolic blood pressure; WC, waist circumference; and WHR,
waist-to-hip ratio.account for the LD among SNPs in this population. Specif-
ically, we determined that at the genome-wide level, the
number of effective tests dropped by 25%–50% for any sin-
gle chromosome as a result of LD. Thus, we reasoned that a
reduction of 25% in the number of tests for an eQTL (or
gene) would set a reasonable threshold. This reduced
2,200 to 1,650 tests, which altered the eQTL-centric signif-
icance threshold to 3 3 105. There were no SNP associa-
tions that met this threshold. When we relaxed the
threshold (p % 0.01), we observed 27 SNP-trait associa-
tions, which represent ten separate eQTL transcripts and
12 traits (Table 2).
Next, we used a stepwise linear regression to investigate
whether the expression level of each of the ten transcripts
correlated with their respective CVD risk trait (shown in
Table 2). As above, the stepwise model factored in the
effects of age, sex, kinship, and genetic structure. Only
models with a significant transcript effect of p < 0.05
were accepted. Table 3 shows the results for the five eQTL
transcripts that met these criteria. When the top-ranked
eQTL-associated SNP was added as a covariate in the regres-
sion model, the prediction scores improved slightly for all
significant correlations. Predictive values (R2) ranged from
0.25 to 0.42 (Table 3).
To our knowledge, the five genes (represented by the
above five transcripts) had no prior direct association with
CVD risk traits. Although five genes is a small number, we
wished to investigate whether they are enriched in a spe-
cific biological pathway or pathways. Therefore, we used
WebGestalt46 to perform pathway-enrichment analysis
and applied Bonferroni correction as a robust filter. This re-
vealed enrichment of purine metabolism (p ¼ 2 3 104),
which included both NME1 (MIM 156490) and PAPSS1
(MIM 603262). The potential biological significance of
this observation is indicated by the role of purine-synthesis
dysregulation in hereditary disorders such as gout and
kidney failure,47 which are both found at high levels in
theNI cohort. In addition,we observed enrichment of insu-
lin signaling (p ¼ 9.4 3 103), which included both NME1
and PRDX1 (MIM 176763); this pathway plays a role in the
metabolic dysfunction seen in CVD and related traits.
We used the STRING48 web server to visualize interactionThe American Joupathways amongNME1, PAPSS1, and PRDX1. The resultant
protein-protein interaction network (Figure 4) verified that
the three genes appear to be significantly enriched and
share biological function. The remaining two genes
(NAAA [MIM 607469] and FN3KRP [MIM 611683]) were
not significantly enriched in any pathways. However,
both have interesting metabolic-related associations.
NAAA is involved in the endocannabinoid system and has
a potential role in obesity through the modulation of
food-seeking behavior.49,50 FN3KRP has been tentatively
associated with diabetes, and measurement of FN3K (MIM
608425) and FN3KRP activity has been proposed in assess-
ing the risk of diabetes.51,52 The SNP (rs1046896) tagging
the FN3KRP eQTL has been previously associated with
glycated hemoglobin levels.53Association with GWAS-Associated CVD Traits
A total of 256 unique genes were represented by the 270
eQTLs. In order to further explore the potential association
between the eQTL and CVD, we interrogated the GWAS
database (accessed February 22, 2013) for overlap with
these 256 genes. Twelve overlapped with genes reportedly
associated with CVD or related traits (Table 4). Eleven of
these were attributed to cis-acting eQTL associations,
whereas one exhibited a trans-acting association. One
eQTL of interest (tagged by rs1476413) maps to MTHFR
(MIM 607093) within 1p36.22; this region has been associ-
ated with blood pressure in several GWASs.54–56 Interest-
ingly, this region was also identified as significantly
associated with SBP in a linkage analysis conducted on
the NI pedigree.24 The linkage study by Bellis et al. identi-
fied the chromosomal region 1p36.22 as associated with
SBP with a LOD score > 2; there is robust support for the
association between this region and SBP by both genetic-
isolate4 and general-population studies.57Discussion
Complex disorders such as CVD are contributed to by the
environment, lifestyle, and underlying genetic signatures
and interactions. NI is a unique population isolate withrnal of Human Genetics 93, 1087–1099, December 5, 2013 1091
Figure 2. eQTL Manhattan Plots
Example Manhattan plots of expression transcript versus SNP associations.




















Figure 3. Genome-wide eQTL Map for the NI Cohort
The eQTLs plotted outside the circle in blue demonstrate cis-
acting loci, whereas those displayed inside the circle in red are
trans-acting loci. The distance from the chromosome corresponds
to the significance of the eQTLs, i.e., further away is more signifi-
cant, and all eQTLs passed the Meff-adjusted threshold (p %
1.84 3 107).increased risk factors for CVD and metabolic-related disor-
ders.22,24 Here, we add to this by showing that the pre-
dicted risks for CVD, T2D, and MetS are all higher in the
NI population than in mainland Australia, supporting
the value of the NI population in the identification of
genetic risk factors. Using the NI cohort, we set out to iden-
tify eQTLs and their associations with CVD-related traits.
Large multigenerational pedigrees from isolated popula-
tions can provide enhanced power to detect disease genes
and estimate the heritability of disease traits.58,59 CVD
traits, along with other complex disorders, are likely to
share an underlying and complex layer of genetic control.
Identifying genomic loci that influence gene expression
levels while associating with disease risk factors can pro-
vide vital information for further functional analyses.
Gene expression levels can vary greatly between
different tissue types, and there is much discussion in the
literature about the utility of using whole blood and
PBMCs in gene expression studies.60,61 Because gene
expression and therefore eQTLs might be tissue spe-
cific,62 it is important to study disease-relevant tissues.10
It is well established that many CVD risk factors are
measured via blood biochemical analyses, i.e., lipid levels
(HDL, LDL, total cholesterol, triglycerides), blood sugar
(glucose), and even markers of inflammation (white blood
cell counts). Environmental influences (such as diet, stress,
and smoking) are also known to affect the overall blood
environment. All of these factors contribute to the local tis-
sue environment and in turn potentially influence gene
expression levels, making expression transcript profiling
of peripheral blood cells a viable tool for investigating
the genetic and nongenetic influences of relevance for dis-
ease pathophysiology and risk assessment. Powell et al.The American Joushowed that gene expression levels in whole blood are
significantly heritable.61 In addition, our population has
a well-established increased risk of CVD, which means
we should have increased power to detect these eQTL
and potential associations. Because the NI population is a
genetic isolate, all individuals share some common envi-
ronmental component(s) (for example, diet), and environ-
ment (as well as cultural influence) has been shown to
directly affect gene expression.63 In addition, there is the
possibility of discovering biomarkers in the blood, an
easily accessible tissue for clinical sampling.
Using a statistical approach whose efficiency has already
been demonstrated in the context of a GWAS-based eQTL-
identification method11 by factoring in the unique genetic
structure of the NI population, we identified 1,712 herita-
ble blood-based expression transcripts. Subsequent ana-
lyses identified 270 significantly associated eQTLs (200
cis-acting and 70 trans-acting) and revealed a genome-
wide eQTL map for NI. Initial results of associations
between heritable transcripts and traits indicated a few
highly heritable expression transcripts that showed poten-
tially meaningful biology in terms of CVD and related
traits. Hyperlipidemia and hypertension are CVD risk fac-
tors. G2MA, which has functions involved in lipid meta-
bolism, exhibited a high heritability (h2 ¼ 0.79) in this
study, and Bellis et al. reported that the NI cohort showed
significant heritability of lipid traits—LDL (h2 ¼ 0.42),
HDL (h2¼ 0.45), and cholesterol (h2¼ 0.41).24 In addition,
several of the more significantly heritable transcripts map-
ped to genes involved in blood-pressure-related pathways.
Therefore, we might be seeing a relationship between trait
and transcript heritability within a functional pathway.
Further validation of our approach is in the identifica-
tion of SNP-transcript associations in genes previously re-
ported to associate with obesity- and CVD-related traits.
A search of the GWAS database revealed several eQTLs
that tagged genes and SNPs with prior association to
CVD and related traits. In addition to this, we note further
validation within a recent genome-wide analysis study
that examined the effect of haplotype on the expression
of cis-QTLs.64 This study identified 24 eQTLs whose genes
have been previously associated with disease. Two tran-
scripts from this study, ILMN_1734830 (1p36.22: MTHFR)
and ILMN_1795336 (10p13: PTER [MIM 604446]), were
also tagged by eQTLs present in the NI population
(Table 4). SNPs within both of these genes have been pre-
viously identified to associate with traits such as blood
pressure,54,55 obesity,65 and homocysteine levels.66MTHFR
resides within 1p36.22 and encodes methylenetetrahydro-
folate reductase, an enzyme that catalyzes the reduction of
methylenetetrahydrofolate to methyltetrahydrofolate, a
cofactor for homocysteine methylation to methionine.67
Genetic variation in this gene influences, among other dis-
orders, susceptibility to occlusive vascular disease68 and
neural-tube defects,69,70 making MTHFR an important
candidate gene for diseases such as hypertension, glau-
coma, and migraines.71,72 Interestingly, the 1p36 regionrnal of Human Genetics 93, 1087–1099, December 5, 2013 1093
Table 2. List of eQTL-Centric Association Results: Significant Hits
Trait SNP Chr Position A1 A2 c2 p Value Probe ID Transcript Gene Transcript Chr eQTL
Glu rs1335051 1 107,460,385 G T 9.78 1.8 3 103 ILMN_2399463 VAV3 1 cis
Glu rs2303565 2 219,253,553 T C 9.33 2.3 3 103 ILMN_1704985 CYP27A1 2 cis
Glu rs1344642 2 219,263,506 G A 9.33 2.3 3 103 ILMN_1704985 CYP27A1 2 cis
Cholesterol rs11373 16 55,102,676 A G 17.30 3.2 3 105 ILMN_1723116 AMFR 16 cis
Cholesterol rs12447395 16 55,086,841 T C 9.42 2.1 3 103 ILMN_1723116 AMFR 16 cis
Cholesterol rs2288055 16 55,059,307 C T 9.25 2.4 3 103 ILMN_1723116 AMFR 16 cis
Cholesterol rs2288056 16 55,076,598 A G 9.25 2.4 3 103 ILMN_1723116 AMFR 16 cis
Cholesterol rs3790113 16 54,942,221 T C 8.82 3.0 3 103 ILMN_1723116 AMFR 16 cis
HDL rs3851117 11 56,993,689 C T 10.13 1.5 3 103 ILMN_1765332 TIMM10 11 cis
HDL rs2848630 11 57,113,483 G A 8.82 3.0 3 103 ILMN_1765332 TIMM10 11 cis
LDL rs11373 16 55,102,676 A G 14.89 1.1 3 104 ILMN_1723116 AMFR 16 cis
Trig rs927340 6 2,968,717 G A 10.42 1.2 3 103 ILMN_1674285 LOC401233 6 cis
Trig rs17106351 14 19,762,145 G A 10.21 1.4 3 103 ILMN_1719158 CTBP1 4 trans
Trig rs9503375 6 2,991,536 T G 9.11 2.5 3 103 ILMN_1674285 LOC401233 6 cis
Trig rs911536 6 2,972,130 G A 8.95 2.8 3 103 ILMN_1674285 LOC401233 6 cis
Weight rs2243523 17 78,273,738 G T 13.41 2.6 3 104 ILMN_1652333 FN3KRP 17 cis
BMI rs2243523 17 78,273,738 G T 12.95 3.2 3 104 ILMN_1652333 FN3KRP 17 cis
WC rs10831551 11 2,194,864 A C 11.75 6.1 3 104 ILMN_1668605 NAAA 4 trans
WC rs2243523 17 78,273,738 G T 11.75 6.1 3 104 ILMN_1652333 FN3KRP 17 cis
WC rs10831570 11 2,199,188 C A 10.81 1.0 3 103 ILMN_1668605 NAAA 4 trans
Hip rs2243523 17 78,273,738 G T 10.62 1.5 3 103 ILMN_1652333 FN3KRP 17 cis
Hip rs10831551 11 2,194,864 A C 9.37 2.8 3 103 ILMN_1668605 NAAA 4 trans
WHR rs2726207 4 108,858,940 A C 9.55 2.0 3 103 ILMN_1781819 PAPSS1 4 cis
SBP rs17526904 8 29,003,762 C T 12.00 7.7 3 104 ILMN_1720059 HMBOX1 8 cis
SBP rs7225515 17 78,389,072 G A 9.53 2.7 3 103 ILMN_1652333 FN3KRP 17 cis
SBP rs1044661 17 78,494,309 G A 9.42 2.9 3 103 ILMN_1652333 FN3KRP 17 cis
DBP rs4793854 17 43,927,132 G A 9.31 2.3 3 103 ILMN_1810274 HOXB2 17 cis
Abbreviations are as follows: A1, allele 1; A2, allele 2; BMI, body mass index; chr, chromosome; DBP, diastolic blood pressure; eQTL, expression quantitative trait
locus; glu, plasma glucose; HDL, high-density lipoprotein; hip, hip circumference; LDL, low-density lipoprotein; SBP, systolic blood pressure; trig, triglycerides;
WC, waist circumference; and WHR, waist-to-hip ratio.has been reported to associate with hypertension in a
Slavic population isolate from Germany.4 This region
has also been previously associated with blood pressure
in the NI population,24 suggesting that our current
approach has potentially pinpointed the functional loci
of this previous linkage hit. It is also interesting to
note that migraines have previously been reported to
exhibit a higher incidence in the NI population25,40 than
in mainland Australia, and MTHFR is a prime functional
candidate.
Further evidence of the ability of our approach to iden-
tify loci of biological significance is provided by the associ-
ation between eQTLs and other genes implicated in CVD
and related traits. VAV3 (MIM 605541) encodes a guanine
nucleotide exchange factor for Rho family GTPases.1094 The American Journal of Human Genetics 93, 1087–1099, DeceVav3-deficient mice have been shown to exhibit tachy-
cardia, systemic arterial hypertension, and extensive car-
diovascular remodelling.73,74 The protein product of
CYP27A1 (MIM 606530) participates in the degradation
of cholesterol to 27-hydroxycholesterol. Macrophages are
one of many cells that express CYP27A1, and it has been
identified that 27-hydroxycholesterol might counteract
the production of inflammatory factors associated with
cardiovascular disease.75 CTBP1 (MIM 602618) belongs to
a family of genes encoding corepressors that regulate the
repression of genes associated with white adipose tissue
and can induce the switch to brown adipose tissue.76 Inter-
estingly, white adipose tissue stores energy in the form of
triglycerides; in this study, we identified an association
between the trans-eQTLs for CTBP1 and triglyceridember 5, 2013




p Value R2 R2 p Value
WHR ILMN_1668605 NAAA 0.021 0.42 <2.2 3 1016
Body fat ILMN_1668605 NAAA 0.007 0.37 <2.2 3 1016
Body fat ILMN_1781819 PAPSS1 0.018 0.37 <2.2 3 1016
Body fat ILMN_1741133 NME1 0.014 0.37 <2.2 3 1016
Weight ILMN_2366388 PRDX1 0.011 0.36 <2.2 3 1016
Weight ILMN_1741133 NME1 0.003 0.37 <2.2 3 1016
SBP ILMN_1652333 FN3KRP 0.033 0.25 3.3 3 1015
Abbreviations are as follows: SBP, systolic blood pressure; and WHR, waist-to-
hip ratio.
Figure 4. STRING Analysis of Protein-Protein Interaction
Network for Three CVD-Trait-Related Candidate Genes: PAPSS1,
PRDX1, and NME1
The thickness of the blue connecting lines indicates the level of
confidence for a given protein-protein interaction. The presence
of a node background indicates that a protein structure is listed
in either the Protein Data Base or the SWISS-MODEL database.levels in the NI population. NAAA is involved in the endo-
cannabinoid system, which has been implicated in obesity
through its ability to attenuate or lower the desire of
finding and consuming food.49,50 Because FN3KRP has
been tentatively suggested to associate with diabetes, mea-
surement of FN3K and FN3KRP activity might be of diag-
nostic value in assessing an individual’s susceptibility to
diabetic complications.51,52
In addition, our candidate loci showed significant
enrichment in several biologically relevant pathways of
interest. Enrichment of NME1 and PAPSS1 in the purine
metabolism pathway could represent a shift in ATP-based
cellular energetics and function. NME1 encodes the A iso-
form of nucleoside diphosphate kinase (NDPK), an enzyme
that catalyzes the reversible exchange of phosphate
between nucleoside diphosphates and nucleoside triphos-
phates.77,78 This phosphate shuttling maintains the bal-
ance between guanosine triphosphate or guanosine
diphosphate and ATP or ADP. As a result, changes in
NDPK levels driven by enrichment of NME1 could have a
significant impact on nucleotide homeostasis and ATP-
dependent energy transfer and signaling within cells.
PAPSS1 encodes phosphoadenosine phosphosulfate syn-
thetase 1, which synthesizes the ubiquitous sulfate donor
phosphoadenosine phosphosulfate (PAPS) from ATP and
organic sulfate. PAPS is a substrate used by sulfotransferase
to sulfonatemetabolites, increasing their solubility to facil-
itate biliary excretion.79 Therefore, enrichment of both
NME1 and PAPSS1 could be indicative of a change in
energy management and the regulation of ATP meta-
bolism. ATP plays a key part in cardiac metabolism
involved in supporting tissue growth, survival, and
contractility. Metabolic remodelling, including changes
in both ATP generation and expression of NDPK, is
commonly observed in individuals with CVD.80–83 There-
fore, shifts in metabolic function such as those indicated
by changes in NME1 and PAPSS1 might be indicative of
increased CVD risk. We also saw enrichment of NME1
and PRDX1 in the insulin pathway. Insulin release is also
dependent on ATP, and enrichment of NME1 could there-
fore mark a downstream change in insulin secretion as aThe American Jouresult of an NDPK-catalyzed rebalance of intracellular
ATP levels. PRDX1 encodes peroxiredoxin 1, which is a
key scavenger of H2O2.
84 H2O2 is known to play a role in
both insulin signaling and resistance.85 PRDX1 enrich-
ment might therefore reflect a change in insulin regulation
that in combination with a change in NDPK activity
might associate with susceptibility to the development of
diabetes. Thus, the observed pattern of enrichment of
NME1, PAPSS1, and PDRX1 might be a marker for a meta-
bolic rebalance in the NI cohort, possibly indicative of
early metabolic dysregulation.
In conclusion, using a pedigree-based approach, we have
generated an eQTL map for the NI cohort and have identi-
fied potential candidate genomic regions that alter gene
expression levels and are at the same time associated
with CVD-related traits. We have observed several loci
that could underlie CVD risk in NI, and all of them have
strongly suggestive biological relevance to disease. We
have also broached the idea that several of these could
potentially be early markers of metabolic risk within the
NI population. Not only do these eQTLs provide insights
into potential functional pathways, but our analyses
have revealed associations of loci, transcripts, and traits
for a specific set of CVD risk factors. We have built upon
previous work in the NI cohort and highlight the impor-
tance of integrative genomic analyses in identifying genes
that play potential roles in the development of complex
disorders.rnal of Human Genetics 93, 1087–1099, December 5, 2013 1095
Table 4. Overlap of eQTL Genes Mapping to Chromosomal Regions Previously Associated with CVD and Related Traits
eQTL Transcript eQTL SNP eQTL p Value Gene Chr Region PubMed ID Disease Trait
ILMN_1734830a rs1476413 1.16 3 109 MTHFR 1 1p36.22 19430483; 21909110 blood pressure
ILMN_1746436 rs9263873 9.74 3 109 HCG27 6 6p21.33 22319020 coronary heart disease
ILMN_1721113 rs9264904 2.16 3 1015 HLA-C 6 6p21.33 22319020 coronary heart disease
ILMN_1718063 rs1051338 1.29 3 1011 LIPA 10 10q23.31 21378988; 21606135 coronary heart disease
ILMN_2400759 rs7313 1.30 3 108 CPVL 7 7p14.3 17903298 diabetes related insulin traits
ILMN_1661631 rs103294 4.69 3 1014 LILRA3 19 19q13.42 20686565 HDL cholesterol
ILMN_1737611 rs2532501 2.02 3 108 VAMP1 12 12p13.31 17903296 hip geometry
ILMN_1804735 rs11700748 9.64 3 1010 CBS 21 21q22.3 20031578 homocysteine levels
ILMN_1734830 rs1476413 1.16 3 109 MTHFR 1 1p36.22 20031578 homocysteine levels
ILMN_1795336a rs7909832 9.63 3 1014 PTER 10 10p13 19151714 obesity
ILMN_1797375 rs2182667 6.51 3 108 KLF12 13 13q22.1 22359512 phospholipid levels (plasma)
ILMN_1722025 rs7736263 1.67 3 109 CPEB4 5 5q35.2 20935629 WHR
ILMN_1727045b rs2835138 1.47 3 107 RASGPR3 2 2p22.3 19421330 hypertension
Abbreviations are as follows: chr, chromosome; eQTL, expression quantitative-trait locus; HDL, high-density lipoprotein; and WHR, waist-to-hip ratio.
aThese eQTLs are also reported in Garnier et al.64
btrans-acting eQTL-SNP cluster on chromosome 21.Supplemental Data
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